linjc16/ctgov huggingface dataset:
FAST-A Study to Evaluate the Efficacy and Safety of Quetiapin IR in Patients With Acute Psychosis

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare the efficacy of quetiapine IR, following rapid titration versus conventional titration in patients with acute psychosis

Conditions
-----------------
Psychotic Disorders, Schizophrenia, Bipolar Disorder

Intervention / Treatment
-----------------
* Drug: Quetiapine
* Procedure: Rating Scales
* Procedure: Self Assessment Form
* Procedure: Blood and urine samples
* Procedure: Sleeping pattern


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: provision of written informed consent male or female, aged 18-65 years requirement of hospitalization and in need for antipsychotic treatment for an acute psychotic episode able to swallow tablets from Day 1 Exclusion Criteria: In-patients who are anticipated to be discharged before evaluation of the primary outcome variable at Day 5 patients with known relevant clinical disease history of syncope, or orthostatic hypotension patients with known neutropenia

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Quetiapine|nan|
|Procedure: Rating Scales|nan|
|Procedure: Self Assessment Form|nan|
|Procedure: Blood and urine samples|nan|
|Procedure: Sleeping pattern|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of Positive and Negative Syndrome Scale-Excitatory Subscale (PANSS-EC) at day 5 compared with baseline at day 1 |  |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Assessment of PANSS-EC at Day 3 and 8. Clinical Global Impression (CGI) at baseline and at Day 5 and 8. FAST (For Acute Seroquel Therapy) rating scale at baseline and at Day 5 and 8. The sleeping pattern (8days). Withdrawals/treatment failures. AE |  |  | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute schizophrenia, schizoaffective disorder, psychosis Not Otherwise Specified (NOS), bipolar mania with psychotic symptoms
Levobupivacaine on Heart Rate Variability (HRV) in Spinal Anesthesia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare if the effect of levobupivacaine on autonomic nervous system smaller than that of bupivacaine.

Detailed Description
-----------------
Obtain the heart rate variability (in means and standard deviation, including the high frequency, low frequency and its ratio) data of before and after spinal anesthesia with ECG (and Heart Rate Variability Analyzer) in 2 groups. Meanwhile, record the blood pressure on each subject.

Official Title
-----------------
Comparison of the Effects of Levobupivacaine and Bupivacaine on Heart Rate Variability in Spinal Anesthesia

Conditions
-----------------
Spinal Anesthesia

Intervention / Treatment
-----------------
* Drug: bupivacaine, levobupivacaine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Indicated for spinal anesthesia Exclusion Criteria: Allergic reaction to local anesthetics Coagulopathy Severe spinal deformity Cardiac diseases Metabolic diseases (such as DM, thyroid or adrenal diseases)

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: Levobupivacaine<br>Lumbar puncture with Levobupivacaine for spinal anesthesia | Drug: bupivacaine, levobupivacaine<br>* intrathecal injection 15 20mg(for Levobupivacaine) or 10 15mg(for Bupivacaine) once<br>|
| Active Comparator: Bupivacaine<br>Lumbar puncture with Bupivacaine for spinal anesthesia | Drug: bupivacaine, levobupivacaine<br>* intrathecal injection 15 20mg(for Levobupivacaine) or 10 15mg(for Bupivacaine) once<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| HRV values |  | 5 minutes after drug administration | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Levobupivacaine, HRV, Spinal Anesthesia, Responses of ANS to these two drugs
Clinical Study of 68Ga Labeled HER2 Affibody Analogues

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to assess the dosimetric properties of the positron emission tomography (PET) imaging probe 68Ga labeled HER2 Affibody analogues and preliminarily evaluate its diagnosis value in patients with breast or gastric tumors.

Detailed Description
-----------------
6 healthy volunteers with whole-body PET/CT scans at 0-1.0, 2.0, 3.0 and 4.0 hours after tracer injection (mean dose, 4.93 ± 0.10 mCi) will be performed. During the imaging period, 1 mL blood samples will be obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, 180 and 240 minutes after the injection, for time-activity curve calculations. The estimated radiation doses will be calculated by using OLINDA/EXM software. 50 patients with breast or gastric tumors will be enrolled for the clinical study, they will be performed with both 68Ga-HER2 Affibody PET/CT and18F-FDG PET/CT scans before surgery. The preoperative images are compared and correlated with the pathologically report. Next, the expression of HER2 will be determined by immunohistochemical staining of the resected brain tumor tissues.

Official Title
-----------------
Clinical Study of 68Ga Labeled HER2 Affibody Analogues in Healthy Volunteers and Patients With Breast or Gastric Tumors

Conditions
-----------------
HER2-positive Breast Cancer and Gastric Cancer

Intervention / Treatment
-----------------
* Drug: 68Ga labeled HER2 Affibody


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with breast or gastric cancers: diagnosed by MR and ready for surgery Exclusion Criteria: refuse or cannot endure surgery pregnant women

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: 68Ga labeled HER2 Affibody|inject the tracer to subjects and perform PET/CT scans|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SUV of organs | The standardized uptake values (SUV) in deferent organs | 0, 0.5, 1.0, 2.0,3.0 and 4.0 hours after injection | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| radioactivity of blood sample | blood samples are obtained specifically at 1, 3, 5, 10, 30,60, 90, 120, 150, 180 and 240 minutes after the injection, for time-radioactivity curve calculations. | 1, 3, 5, 10, 30,60, 90, 120, 150, 180 and 240 minutes |
Jogging in the Change of Osteoporosis

Study Overview
=================
Brief Summary
-----------------
To test the changes in osteoarthritis according to the X-rays, and changes in bone quality before and 1 or more years after beginning the jogging

Detailed Description
-----------------
Patients in this research are given an entry Bone Densitometry（DEXA）scan and are required to advance from 3-minute jogging a day to 10-minute level in daily practice for 1 year as instructed. After 1 year, subsequent DEXA scans are recorded. Interested participants are also encouraged to have hip and spine X-rays, and bone quality studies on study entry and two years later. Actual subject participation, intercurrent illnesses, fractures and changes in medication are self-monitored. Results are calculated by change in bone mineral density in the lumbar spine, hips and femurs by the DEXA scan in the study. Dose-response relationships between the amount of jogging and bone mineral density are sought. Jogging-related fractures and other adverse effects are also noted.

Official Title
-----------------
Jogging in the Change of Osteoporosis

Conditions
-----------------
Osteoporosis

Intervention / Treatment
-----------------
* Behavioral: jogging


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Past DEXA scan and, all within 6 months of study entry, DEXA scan and normal values for: Metabolic panel, TSH, PTH, ESR (or CRP), Vitamin D 25 hydroxy, Vitamin D 1,25 dihydroxy, Urine NTX Exclusion Criteria: Known metabolic bone disease such as osteogenesis imperfecta, current treatment with steroids, chemotherapy, or currently healing fractures of lumbar spine, hips or femurs, severe heart disease

Ages Eligible for Study
-----------------
Minimum Age: 50 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: jogging<br>At least 5 times/week | Behavioral: jogging<br>* Jogging as instructed for 1 year<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DEXA T-score | Bone mineral density change in spine, hip and femur after 1 year of jogging | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of fractures | Number of fractures occurring while in study | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Osteoporosis, Bone Diseases
Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent

Study Overview
=================
Brief Summary
-----------------
Post-marketing, prospective, multicentric, non-randomized registry to evaluate the safety and efficacy of Inspiron Sirolimus Eluting Coronary Stent at the treatment of real-world patients.

Detailed Description
-----------------
Up to 5.0000 patients with native coronary arteries lesions with diameter between 2.5 and 4.0 mm and 34 mm of length treated solely with the Inspiron Sirolimus Eluting Coronary Stent. Stent implantation should be performed according to the Instructions for Use and according to the local practice. It is recommended that ECG and cardiac enzymes are collected before and after procedure. Dual anti-platelet therapy is recommended for at least 6 months after procedure. Patients will be followed at 30 days, 1 and 2 years after procedure.

Official Title
-----------------
Prospective, Multicentric, Post-marketing Registry of Inspiron Sirolimus Eluting Coronary Stent for Treatment of Patients With Native Coronary Artery Lesions (Inspiron Real Life II)

Conditions
-----------------
Coronary Artery Disease

Intervention / Treatment
-----------------
* Device: implant


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: alll patients that have been treated with the Inspiron Sirolimus Eluting Stent older and 18 years Exclusion Criteria: Safein Vein or Left Internal Mammary artery Grafts

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| implanted patients<br>Patients with native coronary artery lesions with diameter between 2.5 and 4.0 and 34 mm of length treated only with the Inspiron Sirolimus eluting Stent | Device: implant<br>* coronary stent implantation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Major Adverse Cardiac Events Rate | Cardiac Death, MI, Target Lesion Revascularization and Stent Thrombosis | 12 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Target Vessel and Lesion Revascularization Rates | Target Vessel and Lesion Revascularization | 24 months | 
| Stent Thrombosis Rate | Stent Thrombosis | 24 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
stent, DES, Inspiron
Evaluation of the Relationship Between Healthy Eating and Intrinsic Capacity in Elderly Individuals

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to evaluate the relationship between intrinsic capacity and healthy eating in elderly individuals.

Detailed Description
-----------------
The relationship between the healthy eating index and intrinsic capacity in elderly individuals is unknown. The aim of this study is to evaluate the relationship between intrinsic capacity and healthy eating in elderly individuals.

Official Title
-----------------
Evaluation of the Relationship Between Healthy Eating and Intrinsic Capacity in Elderly Individuals

Conditions
-----------------
Healthy Eating Index, Muscle Strain, Frailty

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: 65 years and older Those who agreed to participate in the study Orally fed Exclusion Criteria: Not voluntarily participating in the research Having a serious life-threatening condition (critical illness, hospitalization in the intensive care unit, acute complication) Those who do not have a mental disability that cannot answer the questions (Mental retardation, Alzheimer's, etc.) Major psychiatric illness congenital or acquired muscle disease

Ages Eligible for Study
-----------------
Minimum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: no intervention|no intervention|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Relationship between intrinsic capacity and healthy eating | Relationship between intrinsic capacity and healthy eating | 2 week | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
healthy eating, intrinsic capacity, elderly
Early Metabolic Response in Locally Advanced Esophageal Cancer Undergoing Induction Chemoradiotherapy

Study Overview
=================
Brief Summary
-----------------
Early metabolic response evaluation may predict clinical and histopathological response after neoadjuvant chemotherapy. Its value in neoadjuvant chemoradiotherapy (CRT) is unknown. Our aim was to assess the value of early metabolic response after one cycle of chemotherapy using 18-FDG-PET-CT to predict pathological response and outcome in cT2-4 N0/+ esophageal cancer treated by neoadjuvant CRT and esophagectomy.

Official Title
-----------------
Early Metabolic Response Evaluation With 18-FDG PET-CT in Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy

Conditions
-----------------
Esophageal Carcinoma (Squamous Cell Carcinoma - Adenocarcinoma)

Intervention / Treatment
-----------------
* Other: 18-FDG-PET-CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: locally advanced esophageal cancer (cT2-4 N0/+) Exclusion Criteria: PET-CT not performed at UZLeuven Other tumor types Distant metastases (organ)
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| locally advanced esophageal carcinoma (cT2-3N0/+)<br> | Other: 18-FDG-PET-CT<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| early metabolic response to predict pathological response and outcome | assess the value of early metabolic response with 18-FDG-PET-CT (i.e. a decrease of ≥ 35% of SUVmean) after a single cycle of chemotherapy followed by neoadjuvant CRT and esophagectomy as a tool to predict pathological response and outcome in patients with cT2-4N0/+ carcinoma of the esophagus and GE-junction (GEJ). |  | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| to study correlations between early metabolic response, late metabolic response, histopathological response and outcome. |  |  |
Computer Tomography (CT) Trial of Acute Abdomen

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the impact of routinely performed early CT scanning in terms of diagnostic accuracy, patient management and cost-effectiveness compared to current imaging practice in patients suffering from acute abdomen.

Conditions
-----------------
Acute Abdomen

Intervention / Treatment
-----------------
* Procedure: Abdominal contrast-enhanced CT scanning


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: age > 18 abdominal pain > 2h and < 7 days Exclusion Criteria: pregnancy acute abdominal trauma allergy to iodinated contrast media severe renal insufficiency metformin medication combined with elevated plasma creatinin level lack of cooperation (if informed consent is not possible) abdominal pain combined with bleeding shock

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: CT<br>All patients in the CT arm undergo abdominal CT scanning within 24 hours of admission to the ER. | Procedure: Abdominal contrast-enhanced CT scanning<br>* Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning<br>|
| No Intervention: Current practice<br>The patients in the current practice arm are referred to radiological examinations, such as US, plain radiography or CT, based on the clinical need only. | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Diagnostic accuracy |  | at discharge and/or 2-3 mo follow-up |
Study on the microRNA Expression Level in Postmenopausal Osteoporosis

Study Overview
=================
Brief Summary
-----------------
The miRNA plays an important regulation role in gene expression, and also closely related to bone metabolism. Previous research found that postmenopausal osteoporosis with kidney Yin deficiency syndrome (POP) is associated with CLCF1 gene. This project proposed by bioinformatics prediction CLCF1 targeted regulation of miRNAs, and use the 3 'UTR dual luciferase report system for target validation, aimed at the miRNA levels to explore postmenopausal osteoporosis molecular mechanism with kidney Yin deficiency syndrome.

Official Title
-----------------
Study on the Molecular Mechanism in Postmenopausal Osteoporosis With Kidney Yin Deficiency Syndrome Based on miRNA Mediated Gene Translation Regulation Function by Targeting CLCF1

Conditions
-----------------
Postmenopausal Osteoporosis

Intervention / Treatment
-----------------
* Other: osteoporosis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: The Participants who volunteer to be test subjects, and can accept experimental drugs, and promise to finish the course should sign the informed consent. Female ages 45 to 75 had gone through natural menopause before two years In accordance with the western medicine diagnostic criteria of osteoporosis and belong to kidney Yin deficiency syndrome differentiation of traditional Chinese medicine certificate; In accordance with the western medicine diagnostic criteria; In accordance with TCM diagnostic methods; .If any of the above answers are no, The subjects couldn't in the study. Exclusion Criteria: Do not accord with standard of the western medicine diagnosis and TCM diagnostic methods Age: <44 and > 76 years old; With hyperparathyroidism, osteomalacia, rheumatoid arthritis, multiple myeloma and other serious complications such as secondary osteoporosis; Late or deformity, disability, loss of labor; With cardiovascular, cerebrovascular, liver, kidney and hematopoietic system and other serious primary diseases; Psychosis or alzheimer's patients; Nearly three months, the use of hormone replacement therapy (HRT) and taking calcitonin, nearly six months has used double phosphonic acid salt for 15 days, etc.; This medicine allergic constitution or composition of known to have allergies; In a critical condition, It's difficult to make exact evaluators to efficacy and safety of the new drugs;

Ages Eligible for Study
-----------------
Minimum Age: 45 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| osteoporosis,non-osteoporosis<br> | Other: osteoporosis<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| microRNA expression lever in the Peripheral Blood |  | one year |